Page last updated: 2024-12-05

hydralazine hydrochloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Hydralazine hydrochloride is a vasodilator medication used to treat high blood pressure. It works by relaxing the muscles in the blood vessels, which allows blood to flow more easily. The synthesis of hydralazine hydrochloride involves a multi-step process that begins with the reaction of hydrazine with benzaldehyde. The resulting hydrazone is then treated with hydrochloric acid to form the hydrochloride salt. Hydralazine hydrochloride is an important medication for the treatment of high blood pressure. It is effective in lowering blood pressure, and it is relatively safe and well-tolerated. Hydralazine hydrochloride is studied because it is a useful medication for the treatment of high blood pressure. Researchers are also studying hydralazine hydrochloride for its potential use in the treatment of other conditions, such as heart failure and cancer.'

hydralazine hydrochloride : The hydrochloride salt of hydralazine; a direct-acting vasodilator that is used as an antihypertensive agent. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID9351
CHEMBL ID542541
CHEBI ID31672
SCHEMBL ID36271
MeSH IDM0010678

Synonyms (150)

Synonym
hyperazin
hyperex
phthalazinone, monohydrochloride
slow-apresolin
aiselazine
hydralazine monohydrochloride
nsc-89394
apresoline hydrochloride
phthalazine, monohydrochloride
1-hydrazinophthalazine monohydrochloride
lopress
nsc89394
1(2h)-phthalazinone, monohydrochloride
wln: t66 cnnj bmz & gh
1(2h)-phthalazinone, hydrochloride
hydralazine chloride
1-hydrazinophthalazine hydrochloride
dralzine
hydrallazine hydrochloride
AC-18050
apresoline
bpi-103
EU-0100593
hydralazine hydrochloride
304-20-1
PRESTWICK_610
hsdb 434
1(2h)-phthalazinone, hydrazone, monohydrochloride
nsc 89394
nor-press 25
hydralazine hcl
phthalazine, 1-hydrazino-, monohydrochloride
1(2h)-phthalazinone, hydrazone, hydrochloride
apresine
phthalazinone, hydrazone, monohydrochloride
hydralazine hydrochloride [jan]
ccris 334
einecs 206-151-0
rolazine
D01302
apresoline (tn)
hydralazine hydrochloride (jp17/usp)
NCGC00093972-02
NCGC00093972-03
apresoline-esidrix
SPECTRUM1500334
NCGC00093972-04
NCGC00093972-01
hydrochloride, hydralazine
H 1753
phthalazinone hydrazone monohydrochloride
CHEBI:31672 ,
1(2h)-phthalazinone hydrazone hydrochloride
apressinum
hydralazini hydrochloridum
CHEMBL542541
mc-1101
FT-0669283
H0409
HMS1920D17
HMS1568B19
fd171b778y ,
unii-fd171b778y
pra 027
hydralazine hydrochloride [usp:jan]
phthalazine, 1-hydrazinyl-, hydrochloride (1:1)
NCGC00256719-01
dtxsid1044645 ,
tox21_302496
dtxcid9024645
1-hydrazinophthalazinemonohydrochloride
A820366
EN300-03637
1-hydrazinylphthalazine hydrochloride
nsc757058
nsc-757058
pharmakon1600-01500334
tox21_110163
CCG-40185
AKOS008968535
LP00593
hydralazine hydrochloride component of unipres
hydralazine hydrochloride [hsdb]
serpasil-apresoline component hydralazine hydrochloride
hydralazine hydrochloride component of bidil
hydralazine hydrochloride component of hydralazine hydrochloride-hydrochlorothiazide-reserpine
hydralazini hydrochloridum [who-ip latin]
apresazide component hydralazine hydrochloride
hydralazine hydrochloride component of ser-ap-es
apressinum [who-ip]
hydra-zide component hydralazine hydrochloride
hydralazine hydrochloride component of cam-ap-es
hydralazine hydrochloride-hydrochlorothiazide-reserpine component hydralazine hydrochloride
hydralazine hydrochloride component of dralserp
hydralazine hydrochloride [orange book]
unipres component hydralazine hydrochloride
hydralazine hydrochloride [who-ip]
hydralazine hydrochloride [mart.]
hydralazine hydrochloride component of hydrap-es
hydralazine hydrochloride component of hydra-zide
hydroserpine plus (r-h-h) component hydralazine hydrochloride
hydralazine hydrochloride [who-dd]
hydralazine hydrochloride [vandf]
ser-a-gen component hydralazine hydrochloride
apresoline-esidrix component hydralazine hydrochloride
hydralazine hydrochloride [usp impurity]
hydrap-es component hydralazine hydrochloride
hydralazine hydrochloride [mi]
hydralazine hydrochloride [usp monograph]
cam-ap-es component hydralazine hydrochloride
hydralazine hydrochloride component of ser-a-gen
hydralazine hydrochloride component of hydroserpine plus (r-h-h)
ser-ap-es component hydralazine hydrochloride
hydralazine hydrochloride component of serpasil-apresoline
hydralazine hydrochloride component of apresoline-esidrix
dralserp component hydralazine hydrochloride
hydralazine hydrochloride component of apresazide
bidil component hydralazine hydrochloride
hydralazine hydrochloride [usp-rs]
S2562
hydralazine (hydrochloride) ,
HY-B0464
SCHEMBL36271
tox21_110163_1
NCGC00015501-09
1-hydrazinophthalazine hcl
ZUXNZUWOTSUBMN-UHFFFAOYSA-N
NCGC00261278-01
tox21_500593
hydralazinhydrochlorid
Q-201208
hydralazinehydrochloride
AKOS025116605
AKOS028109609
phthalazin-1-ylhydrazine;hydrochloride
Z57980178
sr-01000075903
SR-01000075903-1
SR-01000075903-5
1044569-46-1
Q27114606
CCG-266561
(z)-1-hydrazono-1,2-dihydrophthalazine hydrochloride
hydralazine-15n4hydrochloride
hydralazine hydrochloride (usp:jan)
phthalazin-1-ylhydrazine monohydrochloride
hydralazine hydrochloride (usp-rs)
hydralazine hydrochloride (usp monograph)
hydralazine hydrochloride (mart.)
hydralazine hydrochloride (usp impurity)

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
vasodilator agentA drug used to cause dilation of the blood vessels.
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
hydrochlorideA salt formally resulting from the reaction of hydrochloric acid with an organic base.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (62)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.22390.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency28.18380.004023.8416100.0000AID485290
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency15.02970.140911.194039.8107AID2451
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency27.71700.177814.390939.8107AID2147
LuciferasePhotinus pyralis (common eastern firefly)Potency1.74440.007215.758889.3584AID1224835
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency6.56793.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency1.78100.006038.004119,952.5996AID1159521; AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency2.36150.000714.592883.7951AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency6.62540.180013.557439.8107AID1460; AID1468
AR proteinHomo sapiens (human)Potency9.32850.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743042; AID743054; AID743063
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency30.63790.000657.913322,387.1992AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency8.25990.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency61.13060.000417.946075.1148AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency1.87470.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency50.58410.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency3.32940.001530.607315,848.9004AID1224819; AID1224820; AID1224821; AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency48.96620.375827.485161.6524AID743217
pregnane X nuclear receptorHomo sapiens (human)Potency33.73640.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency8.00250.000229.305416,493.5996AID1259244; AID1259248; AID1259383; AID743069; AID743075; AID743078; AID743079; AID743080; AID743091
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency38.89520.001024.504861.6448AID743215
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency48.96620.023723.228263.5986AID743222
aryl hydrocarbon receptorHomo sapiens (human)Potency9.01740.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency26.53990.001723.839378.1014AID743083
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency58.29290.057821.109761.2679AID1159526; AID1159528
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency0.11220.10009.191631.6228AID1346983
Histone H2A.xCricetulus griseus (Chinese hamster)Potency113.00400.039147.5451146.8240AID1224845
Bloom syndrome protein isoform 1Homo sapiens (human)Potency100.00000.540617.639296.1227AID2364; AID2528
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency47.754823.934123.934123.9341AID1967
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency8.97160.316212.443531.6228AID902; AID924
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency17.78280.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency61.13060.000323.4451159.6830AID743067
histone deacetylase 9 isoform 3Homo sapiens (human)Potency32.50710.037617.082361.1927AID1259364; AID1259388
heat shock protein beta-1Homo sapiens (human)Potency58.29290.042027.378961.6448AID743210; AID743228
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency8.92370.000627.21521,122.0200AID743202; AID743219
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency13.51610.00798.23321,122.0200AID2546; AID2551
survival motor neuron protein isoform dHomo sapiens (human)Potency9.44950.125912.234435.4813AID1458
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency31.62280.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency4.02000.001557.789015,848.9004AID1259244
Integrin beta-3Homo sapiens (human)Potency7.94330.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency7.94330.316211.415731.6228AID924
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency4.02000.001551.739315,848.9004AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency21.57700.011917.942071.5630AID651632; AID720516
Ataxin-2Homo sapiens (human)Potency31.46540.011912.222168.7989AID651632
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Aspartate aminotransferase, cytoplasmicHomo sapiens (human)IC50 (µMol)26.62005.39005.39005.3900AID1850916
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nuclear receptor subfamily 1 group I member 2Rattus norvegicus (Norway rat)EC50 (µMol)0.45000.01004.139410.0000AID1215090
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (122)

Processvia Protein(s)Taxonomy
nucleotide-excision repairN-glycosylase/DNA lyaseHomo sapiens (human)
DNA damage responseN-glycosylase/DNA lyaseHomo sapiens (human)
negative regulation of double-strand break repair via single-strand annealingN-glycosylase/DNA lyaseHomo sapiens (human)
base-excision repairN-glycosylase/DNA lyaseHomo sapiens (human)
regulation of DNA-templated transcriptionN-glycosylase/DNA lyaseHomo sapiens (human)
response to oxidative stressN-glycosylase/DNA lyaseHomo sapiens (human)
response to radiationN-glycosylase/DNA lyaseHomo sapiens (human)
response to xenobiotic stimulusN-glycosylase/DNA lyaseHomo sapiens (human)
response to light stimulusN-glycosylase/DNA lyaseHomo sapiens (human)
response to estradiolN-glycosylase/DNA lyaseHomo sapiens (human)
cellular response to reactive oxygen speciesN-glycosylase/DNA lyaseHomo sapiens (human)
negative regulation of apoptotic processN-glycosylase/DNA lyaseHomo sapiens (human)
positive regulation of gene expression via chromosomal CpG island demethylationN-glycosylase/DNA lyaseHomo sapiens (human)
depurinationN-glycosylase/DNA lyaseHomo sapiens (human)
depyrimidinationN-glycosylase/DNA lyaseHomo sapiens (human)
response to ethanolN-glycosylase/DNA lyaseHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIN-glycosylase/DNA lyaseHomo sapiens (human)
response to folic acidN-glycosylase/DNA lyaseHomo sapiens (human)
cellular response to cadmium ionN-glycosylase/DNA lyaseHomo sapiens (human)
base-excision repair, AP site formationN-glycosylase/DNA lyaseHomo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
gluconeogenesisAspartate aminotransferase, cytoplasmicHomo sapiens (human)
2-oxoglutarate metabolic processAspartate aminotransferase, cytoplasmicHomo sapiens (human)
oxaloacetate metabolic processAspartate aminotransferase, cytoplasmicHomo sapiens (human)
glycerol biosynthetic processAspartate aminotransferase, cytoplasmicHomo sapiens (human)
aspartate metabolic processAspartate aminotransferase, cytoplasmicHomo sapiens (human)
aspartate catabolic processAspartate aminotransferase, cytoplasmicHomo sapiens (human)
glutamate metabolic processAspartate aminotransferase, cytoplasmicHomo sapiens (human)
Notch signaling pathwayAspartate aminotransferase, cytoplasmicHomo sapiens (human)
glutamate catabolic process to aspartateAspartate aminotransferase, cytoplasmicHomo sapiens (human)
glutamate catabolic process to 2-oxoglutarateAspartate aminotransferase, cytoplasmicHomo sapiens (human)
cellular response to insulin stimulusAspartate aminotransferase, cytoplasmicHomo sapiens (human)
response to glucocorticoidAspartate aminotransferase, cytoplasmicHomo sapiens (human)
fatty acid homeostasisAspartate aminotransferase, cytoplasmicHomo sapiens (human)
aspartate biosynthetic processAspartate aminotransferase, cytoplasmicHomo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (40)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingN-glycosylase/DNA lyaseHomo sapiens (human)
damaged DNA bindingN-glycosylase/DNA lyaseHomo sapiens (human)
endonuclease activityN-glycosylase/DNA lyaseHomo sapiens (human)
protein bindingN-glycosylase/DNA lyaseHomo sapiens (human)
microtubule bindingN-glycosylase/DNA lyaseHomo sapiens (human)
oxidized purine nucleobase lesion DNA N-glycosylase activityN-glycosylase/DNA lyaseHomo sapiens (human)
enzyme bindingN-glycosylase/DNA lyaseHomo sapiens (human)
oxidized purine DNA bindingN-glycosylase/DNA lyaseHomo sapiens (human)
8-oxo-7,8-dihydroguanine DNA N-glycosylase activityN-glycosylase/DNA lyaseHomo sapiens (human)
class I DNA-(apurinic or apyrimidinic site) endonuclease activityN-glycosylase/DNA lyaseHomo sapiens (human)
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
L-aspartate:2-oxoglutarate aminotransferase activityAspartate aminotransferase, cytoplasmicHomo sapiens (human)
phosphatidylserine decarboxylase activityAspartate aminotransferase, cytoplasmicHomo sapiens (human)
pyridoxal phosphate bindingAspartate aminotransferase, cytoplasmicHomo sapiens (human)
L-cysteine transaminase activityAspartate aminotransferase, cytoplasmicHomo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (42)

Processvia Protein(s)Taxonomy
nucleusN-glycosylase/DNA lyaseHomo sapiens (human)
nucleoplasmN-glycosylase/DNA lyaseHomo sapiens (human)
mitochondrial matrixN-glycosylase/DNA lyaseHomo sapiens (human)
cytosolN-glycosylase/DNA lyaseHomo sapiens (human)
nuclear matrixN-glycosylase/DNA lyaseHomo sapiens (human)
nuclear speckN-glycosylase/DNA lyaseHomo sapiens (human)
protein-containing complexN-glycosylase/DNA lyaseHomo sapiens (human)
nucleusN-glycosylase/DNA lyaseHomo sapiens (human)
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
nucleusAspartate aminotransferase, cytoplasmicHomo sapiens (human)
cytoplasmAspartate aminotransferase, cytoplasmicHomo sapiens (human)
cytosolAspartate aminotransferase, cytoplasmicHomo sapiens (human)
extracellular exosomeAspartate aminotransferase, cytoplasmicHomo sapiens (human)
cytosolAspartate aminotransferase, cytoplasmicHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (98)

Assay IDTitleYearJournalArticle
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID227479Antihypertensive activity in spontaneously hypertensive rats (SHR) measured by percentage fall in cardiac rhythm (CR) at 1 mg/kg administered intraperitoneally at 24 h;No significance1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Selective thromboxane synthetase inhibitors and antihypertensive agents. New derivatives of 4-hydrazino-5H-pyridazino[4,5-b]indole, 4-hydrazinopyridazino[4,5-a]indole, and related compounds.
AID194654Compound was evaluated for oral antihypertensive activity in spontaneously hypertensive rats at 3 mg/kg peroral administration1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Synthesis and antihypertensive activity of 6,7-disubstituted trans-4-amino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ols.
AID1215092Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 up to 46 uM after 24 hrs by luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID1850920Noncompetitive inhibition of GOT1 (unknown origin) using aspartic acid as substrate assessed as reduction in Vmax with constant Km at 0 to 40 uM by Michaelis-Menten equation based kinetic analysis2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73The discovery of a non-competitive GOT1 inhibitor, hydralazine hydrochloride, via a coupling reaction-based high-throughput screening assay.
AID1850918Binding affinity to GOT1 (unknown origin) assessed as dissociation constant by microscale thermophoresis assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73The discovery of a non-competitive GOT1 inhibitor, hydralazine hydrochloride, via a coupling reaction-based high-throughput screening assay.
AID194644Compound was evaluated for antihypertensive activity in deoxy-corticosterone acetate (DOCA) treated hypertensive rats at 1 mg/kg peroral administration1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Synthesis and antihypertensive activity of 6,7-disubstituted trans-4-amino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ols.
AID1215091Activation of human PXR expressed in human HepG2 (DPX-2) cells up to 46 uM after 24 hrs by luciferase reporter gene based luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID1850917Inhibition of MDH1 (unknown origin)2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73The discovery of a non-competitive GOT1 inhibitor, hydralazine hydrochloride, via a coupling reaction-based high-throughput screening assay.
AID227126Antihypertensive activity in spontaneously hypertensive rats (SHR) measured by percentage fall in arterial pressure (AP) at 1 mg/kg administered intraperitoneally at 3 h1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Selective thromboxane synthetase inhibitors and antihypertensive agents. New derivatives of 4-hydrazino-5H-pyridazino[4,5-b]indole, 4-hydrazinopyridazino[4,5-a]indole, and related compounds.
AID1850916Inhibition of GOT1 (unknown origin)2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73The discovery of a non-competitive GOT1 inhibitor, hydralazine hydrochloride, via a coupling reaction-based high-throughput screening assay.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID227328Percent fall in systolic blood pressure, directly measured on carotid (iv on the jugular vein) of spontaneously hypertensive rats at 1 mg/kg after 240 minutes;No significance1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Selective thromboxane synthetase inhibitors and antihypertensive agents. New derivatives of 4-hydrazino-5H-pyridazino[4,5-b]indole, 4-hydrazinopyridazino[4,5-a]indole, and related compounds.
AID227323Percent fall in systolic blood pressure, directly measured on carotid (iv on the jugular vein) of spontaneously hypertensive rats at 1 mg/kg after 120 minutes1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Selective thromboxane synthetase inhibitors and antihypertensive agents. New derivatives of 4-hydrazino-5H-pyridazino[4,5-b]indole, 4-hydrazinopyridazino[4,5-a]indole, and related compounds.
AID226979Antihypertensive activity in spontaneously hypertensive rats (SHR) measured by percentage fall in arterial pressure (AP) at 1 mg/kg administered intraperitoneally at 24 h;No significance1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Selective thromboxane synthetase inhibitors and antihypertensive agents. New derivatives of 4-hydrazino-5H-pyridazino[4,5-b]indole, 4-hydrazinopyridazino[4,5-a]indole, and related compounds.
AID186528Hypotensive activity evaluated as mean arterial blood pressure (MABP) in saline-loaded spontaneously hypertensive rats dosed (per oral) at 25 mg/kg1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Synthesis and anxiolytic activity of 6-(substituted-phenyl)-1,2,4-triazolo[4,3-b]pyridazines.
AID225603In vitro inhibition of platelet aggregation induced by DD (PRP incubated for 5 minutes at 37 degree C) at 10e-5 M;No significance1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Selective thromboxane synthetase inhibitors and antihypertensive agents. New derivatives of 4-hydrazino-5H-pyridazino[4,5-b]indole, 4-hydrazinopyridazino[4,5-a]indole, and related compounds.
AID1850924Noncompetitive inhibition of GOT1 (unknown origin) using aspartic acid and alpha-ketoglutaric acid as substrate incubated in presence of pyridoxal 5'-phosphate2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73The discovery of a non-competitive GOT1 inhibitor, hydralazine hydrochloride, via a coupling reaction-based high-throughput screening assay.
AID225612In vitro inhibition of platelet aggregation induced by AA (PRP incubated for 60 minutes at 37 degree C) at 10e-5 M;No significance1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Selective thromboxane synthetase inhibitors and antihypertensive agents. New derivatives of 4-hydrazino-5H-pyridazino[4,5-b]indole, 4-hydrazinopyridazino[4,5-a]indole, and related compounds.
AID225578Ex vivo inhibition of platelet aggregation induced by AA at 30 mg/kg; No significance1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Selective thromboxane synthetase inhibitors and antihypertensive agents. New derivatives of 4-hydrazino-5H-pyridazino[4,5-b]indole, 4-hydrazinopyridazino[4,5-a]indole, and related compounds.
AID227480Antihypertensive activity in spontaneously hypertensive rats (SHR) measured by percentage fall in cardiac rhythm (CR) at 1 mg/kg administered intraperitoneally at 3 h1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Selective thromboxane synthetase inhibitors and antihypertensive agents. New derivatives of 4-hydrazino-5H-pyridazino[4,5-b]indole, 4-hydrazinopyridazino[4,5-a]indole, and related compounds.
AID1850925Reversible inhibition of GOT1 (unknown origin) at 10 fold IC50 preincubated for 30 mins followed by dilution to 0.5 fold IC50 and measured after 20 mins by dilution assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73The discovery of a non-competitive GOT1 inhibitor, hydralazine hydrochloride, via a coupling reaction-based high-throughput screening assay.
AID227481Antihypertensive activity in spontaneously hypertensive rats (SHR) measured by percentage fall in cardiac rhythm (CR) at 1 mg/kg administered intraperitoneally at 5 h1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Selective thromboxane synthetase inhibitors and antihypertensive agents. New derivatives of 4-hydrazino-5H-pyridazino[4,5-b]indole, 4-hydrazinopyridazino[4,5-a]indole, and related compounds.
AID194645Compound was evaluated for antihypertensive activity in deoxy-corticosterone acetate (DOCA) treated hypertensive rats at 3 mg/kg peroral administration1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Synthesis and antihypertensive activity of 6,7-disubstituted trans-4-amino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ols.
AID227674Percent increase in cardiac rhythm, directly measured on carotid (iv on the jugular vein) of spontaneously hypertensive rats at 1 mg/kg after 30 minutes1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Selective thromboxane synthetase inhibitors and antihypertensive agents. New derivatives of 4-hydrazino-5H-pyridazino[4,5-b]indole, 4-hydrazinopyridazino[4,5-a]indole, and related compounds.
AID1215090Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID1850922Noncompetitive inhibition of GOT1 (unknown origin) using aspartic acid as substrate assessed as inhibition constant by Michaelis-Menten equation based kinetic analysis2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73The discovery of a non-competitive GOT1 inhibitor, hydralazine hydrochloride, via a coupling reaction-based high-throughput screening assay.
AID227332Percent fall in systolic blood pressure, directly measured on carotid (iv on the jugular vein) of spontaneously hypertensive rats at 1 mg/kg after 60 minutes1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Selective thromboxane synthetase inhibitors and antihypertensive agents. New derivatives of 4-hydrazino-5H-pyridazino[4,5-b]indole, 4-hydrazinopyridazino[4,5-a]indole, and related compounds.
AID40664In vitro inhibition of [3H]-diazepam binding towards Benzodiazepine receptor at 1 uM; Not tested.1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Synthesis and anxiolytic activity of 6-(substituted-phenyl)-1,2,4-triazolo[4,3-b]pyridazines.
AID225584Ex vivo inhibition of platelet aggregation induced by ADP-II at 50 mg/kg; No significance1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Selective thromboxane synthetase inhibitors and antihypertensive agents. New derivatives of 4-hydrazino-5H-pyridazino[4,5-b]indole, 4-hydrazinopyridazino[4,5-a]indole, and related compounds.
AID227677Percent increase in cardiac rhythm, directly measured on carotid (iv on the jugular vein) of spontaneously hypertensive rats at 1 mg/kg after 15 minutes1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Selective thromboxane synthetase inhibitors and antihypertensive agents. New derivatives of 4-hydrazino-5H-pyridazino[4,5-b]indole, 4-hydrazinopyridazino[4,5-a]indole, and related compounds.
AID227324Percent fall in systolic blood pressure, directly measured on carotid (iv on the jugular vein) of spontaneously hypertensive rats at 1 mg/kg after 15 minutes1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Selective thromboxane synthetase inhibitors and antihypertensive agents. New derivatives of 4-hydrazino-5H-pyridazino[4,5-b]indole, 4-hydrazinopyridazino[4,5-a]indole, and related compounds.
AID194643Compound was evaluated for antihypertensive activity in deoxy-corticosterone acetate (DOCA) treated hypertensive rats at 10 mg/kg peroral administration1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Synthesis and antihypertensive activity of 6,7-disubstituted trans-4-amino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ols.
AID226976Antihypertensive activity in spontaneously hypertensive rats (SHR) measured by percentage fall in arterial pressure (AP) at 1 mg/kg administered intraperitoneally at 1 h1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Selective thromboxane synthetase inhibitors and antihypertensive agents. New derivatives of 4-hydrazino-5H-pyridazino[4,5-b]indole, 4-hydrazinopyridazino[4,5-a]indole, and related compounds.
AID227335Percent increase in cardiac rhythm, directly measured on carotid (iv on the jugular vein) of spontaneously hypertensive rats at 1 mg/kg after 60 minutes;No significance1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Selective thromboxane synthetase inhibitors and antihypertensive agents. New derivatives of 4-hydrazino-5H-pyridazino[4,5-b]indole, 4-hydrazinopyridazino[4,5-a]indole, and related compounds.
AID225574Ex vivo inhibition of platelet aggregation induced by AA at 100 mg/kg1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Selective thromboxane synthetase inhibitors and antihypertensive agents. New derivatives of 4-hydrazino-5H-pyridazino[4,5-b]indole, 4-hydrazinopyridazino[4,5-a]indole, and related compounds.
AID227675Percent increase in cardiac rhythm, directly measured on carotid (iv on the jugular vein) of spontaneously hypertensive rats at 1 mg/kg after 5 minutes;No significance1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Selective thromboxane synthetase inhibitors and antihypertensive agents. New derivatives of 4-hydrazino-5H-pyridazino[4,5-b]indole, 4-hydrazinopyridazino[4,5-a]indole, and related compounds.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID40662in vitro inhibition of [3H]diazepam binding against rat Benzodiazepine receptor1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Synthesis and anxiolytic activity of 6-(substituted-phenyl)-1,2,4-triazolo[4,3-b]pyridazines.
AID227673Percent fall in systolic blood pressure, directly measured on carotid (iv on the jugular vein) of spontaneously hypertensive rats at 1 mg/kg after 180 minutes;No significance1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Selective thromboxane synthetase inhibitors and antihypertensive agents. New derivatives of 4-hydrazino-5H-pyridazino[4,5-b]indole, 4-hydrazinopyridazino[4,5-a]indole, and related compounds.
AID1850923Noncompetitive inhibition of GOT1 (unknown origin) using alpha-Ketoglutaric acid as substrate assessed as inhibition constant by Michaelis-Menten equation based kinetic analysis2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73The discovery of a non-competitive GOT1 inhibitor, hydralazine hydrochloride, via a coupling reaction-based high-throughput screening assay.
AID227676Percent increase in cardiac rhythm, directly measured on carotid (iv on the jugular vein) of spontaneously hypertensive rats at 1 mg/kg after 75 minutes;No significance1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Selective thromboxane synthetase inhibitors and antihypertensive agents. New derivatives of 4-hydrazino-5H-pyridazino[4,5-b]indole, 4-hydrazinopyridazino[4,5-a]indole, and related compounds.
AID1215088Competitive binding affinity to human PXR LBD (111 to 434) up to 46 uM by TR-FRET assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID225580Ex vivo inhibition of platelet aggregation induced by AA at 50 mg/kg; No significance1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Selective thromboxane synthetase inhibitors and antihypertensive agents. New derivatives of 4-hydrazino-5H-pyridazino[4,5-b]indole, 4-hydrazinopyridazino[4,5-a]indole, and related compounds.
AID1850927Inhibition of cell proliferation in human MDA-MB-468 cells at 100 uM2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73The discovery of a non-competitive GOT1 inhibitor, hydralazine hydrochloride, via a coupling reaction-based high-throughput screening assay.
AID227333Percent fall in systolic blood pressure, directly measured on carotid (iv on the jugular vein) of spontaneously hypertensive rats at 1 mg/kg after 75 minutes1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Selective thromboxane synthetase inhibitors and antihypertensive agents. New derivatives of 4-hydrazino-5H-pyridazino[4,5-b]indole, 4-hydrazinopyridazino[4,5-a]indole, and related compounds.
AID1850921Noncompetitive inhibition of GOT1 (unknown origin) using alpha-Ketoglutaric acid as substrate assessed as reduction in Vmax with constant Km at 0 to 40 uM by Michaelis-Menten equation based kinetic analysis2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73The discovery of a non-competitive GOT1 inhibitor, hydralazine hydrochloride, via a coupling reaction-based high-throughput screening assay.
AID225615In vitro inhibition of platelet aggregation induced by ADP-II (PRP incubated for 5 minutes at 37 degree C) at 10e-5 M;No significance1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Selective thromboxane synthetase inhibitors and antihypertensive agents. New derivatives of 4-hydrazino-5H-pyridazino[4,5-b]indole, 4-hydrazinopyridazino[4,5-a]indole, and related compounds.
AID221446Acute toxicity in mice was expressed as lethal dose;No significance1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Selective thromboxane synthetase inhibitors and antihypertensive agents. New derivatives of 4-hydrazino-5H-pyridazino[4,5-b]indole, 4-hydrazinopyridazino[4,5-a]indole, and related compounds.
AID227337Antihypertensive activity in spontaneously hypertensive rats (SHR) measured by percentage fall in cardiac rhythm (CR) at 1 mg/kg administered intraperitoneally at 1 h1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Selective thromboxane synthetase inhibitors and antihypertensive agents. New derivatives of 4-hydrazino-5H-pyridazino[4,5-b]indole, 4-hydrazinopyridazino[4,5-a]indole, and related compounds.
AID227331Percent fall in systolic blood pressure, directly measured on carotid (iv on the jugular vein) of spontaneously hypertensive rats at 1 mg/kg after 5 minutes1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Selective thromboxane synthetase inhibitors and antihypertensive agents. New derivatives of 4-hydrazino-5H-pyridazino[4,5-b]indole, 4-hydrazinopyridazino[4,5-a]indole, and related compounds.
AID227329Percent fall in systolic blood pressure, directly measured on carotid (iv on the jugular vein) of spontaneously hypertensive rats at 1 mg/kg after 30 minutes1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Selective thromboxane synthetase inhibitors and antihypertensive agents. New derivatives of 4-hydrazino-5H-pyridazino[4,5-b]indole, 4-hydrazinopyridazino[4,5-a]indole, and related compounds.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID194652Compound was evaluated for oral antihypertensive activity in spontaneously hypertensive rats at 10 mg/kg peroral administration1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Synthesis and antihypertensive activity of 6,7-disubstituted trans-4-amino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ols.
AID225582Ex vivo inhibition of platelet aggregation induced by ADP-II at 30 mg/kg; No significance1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Selective thromboxane synthetase inhibitors and antihypertensive agents. New derivatives of 4-hydrazino-5H-pyridazino[4,5-b]indole, 4-hydrazinopyridazino[4,5-a]indole, and related compounds.
AID227128Antihypertensive activity in spontaneously hypertensive rats (SHR) measured by percentage fall in arterial pressure (AP) at 1 mg/kg administered intraperitoneally at 5 h1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Selective thromboxane synthetase inhibitors and antihypertensive agents. New derivatives of 4-hydrazino-5H-pyridazino[4,5-b]indole, 4-hydrazinopyridazino[4,5-a]indole, and related compounds.
AID194653Compound was evaluated for oral antihypertensive activity in spontaneously hypertensive rats at 1 mg/kg peroral administration1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Synthesis and antihypertensive activity of 6,7-disubstituted trans-4-amino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ols.
AID225739In vitro inhibition of platelet aggregation induced by ADP-II (PRP incubated for 60 minutes at 37 degree C) at 10e-5 M;No significance1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Selective thromboxane synthetase inhibitors and antihypertensive agents. New derivatives of 4-hydrazino-5H-pyridazino[4,5-b]indole, 4-hydrazinopyridazino[4,5-a]indole, and related compounds.
AID1215097Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis relative to dexamethasone2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID1850926Inhibition of cell proliferation in human MCF7 cells at 100 uM2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73The discovery of a non-competitive GOT1 inhibitor, hydralazine hydrochloride, via a coupling reaction-based high-throughput screening assay.
AID225576Ex vivo inhibition of platelet aggregation induced by ADP-II at 100 mg/kg; No significance1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Selective thromboxane synthetase inhibitors and antihypertensive agents. New derivatives of 4-hydrazino-5H-pyridazino[4,5-b]indole, 4-hydrazinopyridazino[4,5-a]indole, and related compounds.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (14.29)18.7374
1990's0 (0.00)18.2507
2000's1 (4.76)29.6817
2010's9 (42.86)24.3611
2020's8 (38.10)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 66.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index66.15 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index5.28 (4.65)
Search Engine Demand Index106.18 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (66.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.76%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (95.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]